FDA Advisory Panel Favors Celltrion's Biosimilar of J&J Drug

FDA Advisory Panel Favors Celltrion's Biosimilar of J&J Drug

Feb. 9 — The FDA's Arthritis Advisory Committee Feb. 9 voted 21-3 in favor of a biosimilar of Johnson & Johnson's rheumatoid arthritis treatment Remicade, which, if the FDA approves it, would be the second biosimilar approved in the U.S. and the

(Visited 1 times, 1 visits today)
4
Like
Save

Comments

Comments are disabled for this post.